Amicus Therapeutics: Leveraging the Genetic Revolution

Amicus Therapeutics: Leveraging the Genetic Revolution

Amicus Therapeutics is a pharmaceutical company headquartered in Cranbury, NJ and dedicated to developing treatments for rare and orphan diseases. The company was founded in 2002 and has been publically traded on the NASDAQ since 2007. John F. Crowley has served as the CEO since 2005.


Pharmaceutical investment in rare diseases has always been limited because it is difficult to justify research and development expenses when the potential market for a drug is small. Modern biotechnological advances, however, allow innovative companies like Amicus Therapeutics to develop treatments for these diseases at a fraction of the cost of traditional, brute-force approaches. As such, Amicus Therapeutics currently has a pipeline of several promising pharmaceuticals that are expected to reach the market in the coming years.


Furthest along in development is Migalastat, which is already approved for use in patients in the European Union. Amicus Therapeutics has developed Migalastat as a personalized-medicine treatment for the systematic genetic condition known as Fabry disease. Personalized medicine means that a specific biological pharmaceutical (i.e., a protein) given to each patient is custom-designed based on the genetic abnormalities causing their particular manifestation of the disease.


The product candidate SD-101, which is in phase-three clinical trials, could become the first commercially available treatment for Epidermolysis bullosa, a genetic disease of the connective tissue. This condition, which occurs in only nine out of every million people in the general population, highlights the commitment of Amicus Therapeutics to tackling truly rare diseases (GoogleFinance).


Amicus Therapeutics has, in stage-two clinical trials, an enzyme-replacement therapy, currently referred to as ATB200/AT2221, for Pompe disease. This condition results in the buildup of excess glycogen around the body’s cells and is caused by a deleterious genetic mutation in the enzyme alpha-glucosidase. The therapy for Pompe disease, and for other diseases being investigated by Amicus Therapeutics, involves replacing these defective enzymes with correct versions synthesized in the laboratory.


The primary goal of the Human Genome Project was to obtain insights leading to new frontiers in medicine. With just 92 employees, small and nimble Amicus Therapeutics is now leveraging the tools of the genetic revolution to make this vision a reality.

More about Amicus Therapeutics at

Getting close and personal with Memorial Health CEO, Maggie Gill

Getting close and personal with Memorial Health CEO, Maggie Gill

Maggie Gill is the president and CEO at memorial health. When she started out with the company in 2005, she was a Vice President of the managed care section. A year later, she had risen to the post of chief operations officer. She was very efficient in her work and this led to her appointment to the current leadership position after six years with the company. Currently, she is the one in charge of all the vice presidents, the physicians and their leaders and everyone else who holds a junior position at Memorial health.

Before she started working with the group, there are several other places where she worked. These include her position as the chief financial officer with the Tenet South Florida Health Care systems. She has also worked at the North Shore Medical Center, and also the Coral Gables Hospital in Florida.


Rise to the top

Maggie is a graduate of the University of Miami where she studied finance. She then proceeded to the St. Leo University where she got her MBS and attended the cases at the Wharton School of strategic thinking and management. One of the things that she believes in about succeeding in business is that to make it as an employee or leader at the work place, it is important to create a balance between the life in the home and the work place. He states that when one of these sectors suffer, all the others do.

When asked about the work ethic and the business leadership skills that have contributed to her success, she stated that people make the mistake of treating the workplace as grounds for endless competition. In her opinion, if one is to succeed, either at an individual level or a business entity, it is very important to learn the value of cooperation. These are the values she has always emphasized at her work place and as a result, the organization has become one of the most successful and received many awards under her leadership. She hopes that with time, she will manage to do even more to transform this organization and even take it to the next level of success.

When she is not busy at work, the things that she like spending time with her family and taking part in a variety of charities. She believes that to get the best out of the work situation, giving back to the community is very important.